Wenjie Shi
Wenjie Shi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bingjian Wang
The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University
1 shared publication - Chengbing Huang
Department of Psychiatry, Huaian No. 3 People's Hospital, and Teaching Hospital of Xuzhou Medical University, No. 272 West Huaihai Road, Huai'an, Zip code: 223001 Jiangsu China
1 shared publication - Congjie Wang
Department of Psychiatry, Huai’an No. 3 People’s Hospital, Huai’an 223001, Jiangsu, China
1 shared publication - Gang Chen
Huai'an No.3 People's Hospital, Huai'an, China; Huaian Second Clinical College of Xuzhou Medical University, Huai'an, China
1 shared publication Jia Wang
Huai'an No.3 People's Hospital
1 shared publication- Jiannan Zhu
Department of Psychiatric Huai'an Third People's Hospital Huai'an China
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1903721
Heart rate variability in epilepsy and its association with disease duration: a retrospective case–control study
Objective: To characterize 24-h heart rate variability (HRV) profiles in patients with epilepsy, investigate the association between the standard deviation of normal-to-normal R-R intervals (SDNN) and epilepsy status as well as disease duration, and explore whether hippocampal atrophy and seizure type modify these associations. Methods: This single-center retrospective case–control study enrolled 360 participants (180 patients with epilepsy and 180 non-epileptic controls). HRV parameters—including SDNN, RMSSD, pNN50, LF, HF, and LF/HF ratio—were derived from 24-h ambulatory electrocardiographic recordings, with SDNN prespecified as the primary outcome measure. Multivariable linear regression was used to assess the association between epilepsy status and SDNN. Within the epilepsy cohort, partial correlation analysis, multivariable linear regression, linear trend testing, and subgroup interaction analyses were performed to evaluate the association between disease duration and SDNN. Results: Compared with controls, the epilepsy group exhibited significantly lower SDNN, RMSSD, LF, and HF values, and a higher LF/HF ratio. Multivariable linear regression revealed that epilepsy status was independently associated with lower SDNN. After adjustment for available confounders, longer disease duration was significantly correlated with lower SDNN ( r = −0.573, p < 0.001); each 1-year increase in disease duration was associated with a 1.085 ms decrease in SDNN (95% CI: −1.327 to −0.842, p < 0.001). Linear trend analysis demonstrated a declining SDNN trajectory with increasing disease duration. Subgroup analyses revealed consistent association patterns across subgroups, with no statistically significant interaction effects detected. Conclusion: Patients with epilepsy exhibit HRV abnormalities characterized by reduced SDNN, and prolonged disease duration is associated with reduced SDNN. As a simple and non-invasive parameter, SDNN may be useful in reflecting autonomic regulation status in patients with epilepsy and in providing supplementary information for clinical evaluation. However, due to the limitations of the retrospective study design and the composition of the control group, whether the observed HRV abnormalities are specific to epilepsy remains unclear, and further multicenter prospective studies are warranted for validation.
- 3 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1903721
Open AccessHeart rate variability in epilepsy and its association with disease duration: a retrospective case–control study
Objective: To characterize 24-h heart rate variability (HRV) profiles in patients with epilepsy, investigate the association between the standard deviation of normal-to-normal R-R intervals (SDNN) and epilepsy status as well as disease duration, and explore whether hippocampal atrophy and seizure type modify these associations. Methods: This single-center retrospective case–control study enrolled 360 participants (180 patients with epilepsy and 180 non-epileptic controls). HRV parameters—including SDNN, RMSSD, pNN50, LF, HF, and LF/HF ratio—were derived from 24-h ambulatory electrocardiographic recordings, with SDNN prespecified as the primary outcome measure. Multivariable linear regression was used to assess the association between epilepsy status and SDNN. Within the epilepsy cohort, partial correlation analysis, multivariable linear regression, linear trend testing, and subgroup interaction analyses were performed to evaluate the association between disease duration and SDNN. Results: Compared with controls, the epilepsy group exhibited significantly lower SDNN, RMSSD, LF, and HF values, and a higher LF/HF ratio. Multivariable linear regression revealed that epilepsy status was independently associated with lower SDNN. After adjustment for available confounders, longer disease duration was significantly correlated with lower SDNN ( r = −0.573, p < 0.001); each 1-year increase in disease duration was associated with a 1.085 ms decrease in SDNN (95% CI: −1.327 to −0.842, p < 0.001). Linear trend analysis demonstrated a declining SDNN trajectory with increasing disease duration. Subgroup analyses revealed consistent association patterns across subgroups, with no statistically significant interaction effects detected. Conclusion: Patients with epilepsy exhibit HRV abnormalities characterized by reduced SDNN, and prolonged disease duration is associated with reduced SDNN. As a simple and non-invasive parameter, SDNN may be useful in reflecting autonomic regulation status in patients with epilepsy and in providing supplementary information for clinical evaluation. However, due to the limitations of the retrospective study design and the composition of the control group, whether the observed HRV abnormalities are specific to epilepsy remains unclear, and further multicenter prospective studies are warranted for validation.
- Open Access
- 22 December 2017
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 16 (1) , 1-9
The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial
Differences in effectiveness and tolerability between different atypical antipsychotics may affect schizophrenic patients’ treatment adherence or prognosis. However, which kind of antipsychotic was more effective and safe in the treatment of schizophrenia is still being debated. This study attempted to understand whether there are any differences in efficacy, acceptability, and safety between the five atypical antipsychotics in patients with first-episode schizophrenia. Two hundred cases of inpatients with first-episode drug-naïve schizophrenia were randomly assigned to 6–8 weeks of treatment with either of aripiprazole, risperidone, quetiapine, olanzapine, or ziprasidone from October 2012 to November 2014. The efficacy, acceptability, and safety measurement after 6–8 weeks of treatment of the five kinds of antipsychotics were evaluated by the deduction rate of Brief Psychiatric Rating Scale (BPRS) total score, the proportion of treatment discontinuation, and adverse events, respectively. Whether the treatment discontinuation or combination therapy for baseline antipsychotics after titration mainly depended on ineffective or less effective on an initial-assigned antipsychotic during the study period. BPRS total scores in each antipsychotic group were significantly decreased at the end of the study (P < 0.01), and only the deduction rate of BPRS total scores in the risperidone group was markedly higher than those in the groups of aripiprazole (P < 0.01) and olanzapine (P < 0.05) after controlling the impact of the differences of age of onset. There were significant differences between quetiapine (χ 2 = 5.46, P = 0.019), olanzapine (χ 2 = 5.6, P = 0.018), and ziprasidone regarding the proportion of maintaining on initially allocated therapy. In addition, the difference in treatment discontinuation between male and female patients was also significant (χ 2 = 9.897, P = 0.002), and odds ratio of treatment discontinuation in male and female patients was 0.37 (95% CI 0.198–0.693); however, no difference in treatment discontinuation was found between five antipsychotics. Extrapyramidal symptoms in the groups of quetiapine and olanzapine were notably less than the other three kinds of antipsychotics (P < 0.05), but there were no significant differences in other adverse events between the five antipsychotic groups. Risperidone was more effective than aripiprazole and olanzapine in treating first-episode schizophrenia. The present study revealed the superiority of quetiapine and olanzapine over ziprasidone with remarkably less severe extrapyramidal adverse effects, especially with lower drop-out and treatment discontinuation. There were no differences in terms of other adverse events although the risk of treatment discontinuation was higher in female patients. Trial registration 2012-3-88. Registered 20 July 2012
- 22 December 2017
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 16 (1) , 1-9
Open AccessThe efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial
Differences in effectiveness and tolerability between different atypical antipsychotics may affect schizophrenic patients’ treatment adherence or prognosis. However, which kind of antipsychotic was more effective and safe in the treatment of schizophrenia is still being debated. This study attempted to understand whether there are any differences in efficacy, acceptability, and safety between the five atypical antipsychotics in patients with first-episode schizophrenia. Two hundred cases of inpatients with first-episode drug-naïve schizophrenia were randomly assigned to 6–8 weeks of treatment with either of aripiprazole, risperidone, quetiapine, olanzapine, or ziprasidone from October 2012 to November 2014. The efficacy, acceptability, and safety measurement after 6–8 weeks of treatment of the five kinds of antipsychotics were evaluated by the deduction rate of Brief Psychiatric Rating Scale (BPRS) total score, the proportion of treatment discontinuation, and adverse events, respectively. Whether the treatment discontinuation or combination therapy for baseline antipsychotics after titration mainly depended on ineffective or less effective on an initial-assigned antipsychotic during the study period. BPRS total scores in each antipsychotic group were significantly decreased at the end of the study (P < 0.01), and only the deduction rate of BPRS total scores in the risperidone group was markedly higher than those in the groups of aripiprazole (P < 0.01) and olanzapine (P < 0.05) after controlling the impact of the differences of age of onset. There were significant differences between quetiapine (χ 2 = 5.46, P = 0.019), olanzapine (χ 2 = 5.6, P = 0.018), and ziprasidone regarding the proportion of maintaining on initially allocated therapy. In addition, the difference in treatment discontinuation between male and female patients was also significant (χ 2 = 9.897, P = 0.002), and odds ratio of treatment discontinuation in male and female patients was 0.37 (95% CI 0.198–0.693); however, no difference in treatment discontinuation was found between five antipsychotics. Extrapyramidal symptoms in the groups of quetiapine and olanzapine were notably less than the other three kinds of antipsychotics (P < 0.05), but there were no significant differences in other adverse events between the five antipsychotic groups. Risperidone was more effective than aripiprazole and olanzapine in treating first-episode schizophrenia. The present study revealed the superiority of quetiapine and olanzapine over ziprasidone with remarkably less severe extrapyramidal adverse effects, especially with lower drop-out and treatment discontinuation. There were no differences in terms of other adverse events although the risk of treatment discontinuation was higher in female patients. Trial registration 2012-3-88. Registered 20 July 2012